Navigation Links
PathoGenetix Names Ann Merrifield as Chief Executive Officer and Prepares to Launch Unique Bacterial Identification Technology
Date:12/5/2012

Woburn, MA (PRWEB) December 05, 2012

PathoGenetix, Inc., a commercial-stage developer of an automated system for rapid identification and typing of bacteria strains, today announced that Ann Merrifield has joined the company as President and CEO. Ms. Merrifield takes the lead as PathoGenetix prepares to launch the first commercial system of its proprietary Genome Sequence Scanning (GSS) technology for food safety testing and outbreak investigation. PathoGenetix will provide its automated, benchtop technology to food industry and government customers beginning in 2013.

Ms. Merrifield has spent much of her career leading the development of high growth, profitable biotechnology businesses in biologics, diagnostic services and devices. Prior to PathoGenetix, Ms. Merrifield spent 18 years at Genzyme Corporation, a diversified, global biotechnology company, where she served as President of both the Genzyme Biosurgery and Genzyme Genetics businesses. Prior to Genzyme, Ms. Merrifield was a partner with Bain & Company, Inc.

“Ann Merrifield is the ideal leader to set direction, drive commercialization and develop partnerships for PathoGenetix as we transition from technology development to commercial application of Genome Sequence Scanning,” said PathoGenetix board member, Steve Gullans, Ph.D. “Ann’s success in ramping revenues for revolutionary scientific products is a perfect match for PathoGenetix at this stage.” Dr. Gullans is a co-founder and partner at Excel Venture Management, and was a faculty member at Harvard Medical School and Brigham and Women's Hospital for nearly 20 years.

Originally developed to identify microbial bioterrorism threats, Genome Sequence Scanning is a breakthrough in bacterial identification technology that offers new levels of speed, automation and accuracy for food safety testing and public health investigations of foodborne pathogen outbreaks. The market for effective pathogen confirmation and identification tools for outbreak investigations is estimated at $250 million, and is growing at greater than 10% per year.

“Genome Sequence Scanning is an innovative and powerful new platform for bacterial identification and typing,” Ms. Merrifield said. “I look forward to working with the talented team at PathoGenetix to bring the significant benefits of GSS into the food safety market."

When a pathogen is detected in a food production facility—or worse, is making people sick in multiple locations or states—an investigation is undertaken to identify the organism and trace it back to its source. Current identification systems require time-consuming sample preparation to isolate the bacteria, followed by complex protocols that often produce inconsistent results, even when run by the most skilled operators.

In just four hours, Genome Sequence Scanning extracts microbial DNA from enriched food or clinical samples to confirm and characterize foodborne pathogens. The strain information provided is comparable to pulsed field gel electrophoresis (PFGE), the current gold standard for food pathogen outbreak investigations. Yet because GSS does not require a cultured isolate, it is compatible with sample preparation protocols that are often used with the newer, rapid detection methods that are increasingly in use in clinical and food safety testing laboratories. Its automated platform and simplified protocol require minimal training and ensure consistent, accurate results.

About PathoGenetix, Inc.
PathoGenetix, Inc., is a commercial-stage developer of a rapid, single-molecule analysis technology for bacterial strain typing and identification. Proprietary Genome Sequence Scanning (GSS) is a breakthrough in microbial identification that works directly from complex samples and provides results in just four hours—days faster than current microbiological identification methods. The simplified protocol and automated platform require minimal training and ensure consistent results. PathoGenetix is currently developing a compact, benchtop GSS system for use in food safety testing and outbreak investigation, which will be available in 2013. Learn more at http://www.pathogenetix.com

Read the full story at http://www.prweb.com/releases/pathogenetix/bacterial-identification/prweb10201022.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. AtheroNova Names New Director
2. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
3. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
4. Islet Sciences Names Richard A. Franco, Sr. to its Board of Directors
5. Elsevier / MEDai Names Dr. Peter Edelstein as Chief Medical Officer and Dr. Gerald Osband as Director of Product Strategy
6. PharmaVOICE Names Four inVentiv Health Associates Among "100 Most Inspiring" Leaders in Healthcare
7. Lloyd Library and Museum Names ABCs Blumenthal to New Honorary Advisory Board
8. Ethical Corporation Names Life Technologies First CSO Sustainability Executive of the Year
9. Triple-S Management Corporation Announces the Retirement of Socorro Rivas-Rodriguez; Names Pablo Almodovar Scalley as Successor
10. 23andMe Names Andy Page to Board of Directors
11. Biggest Names in Pharmaceutical, Healthcare Industry to Gather for Groundbreaking Event in Parsippany, New Jersey on September 11-12, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving Tree Wellness ... targeting the needs of consumers who are incorporating medical marijuana into their wellness ... Arizona. , As operators of two successful Valley dispensaries, The Giving Tree’s two ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... Hi-C metagenome deconvolution product, featuring the first commercially available Hi-C kit. Researchers ... perform Hi-C metagenome deconvolution using their own facilities, supplementing the company’s full-service ...
(Date:10/6/2017)... ... October 06, 2017 , ... ... discussion and webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). ... Institute. The event is free and open to the public, but registration is ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market by ... Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast to ... USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, at ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... , April 11, 2017 NXT-ID, Inc. ... technology company, announces the appointment of independent Directors Mr. ... to its Board of Directors, furthering the company,s corporate governance ... Gino ... we look forward to their guidance and benefiting from their ...
(Date:4/5/2017)... April 4, 2017 KEY FINDINGS ... expand at a CAGR of 25.76% during the forecast ... the primary factor for the growth of the stem ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem cell ... application, and geography. The stem cell market of the ...
Breaking Biology News(10 mins):